TNFSF10 and neoplasm: TRAIL-inducing compounds are a novel class of TRAIL-based therapy that engage tumors and the host system to upregulate TRAIL and potentially sensitize tumor cells to its pro-apoptotic activity through dual death receptor and ligand induction, as seen with TIC9 and ONC201/TIC10.